TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25017448

Group type: EXPERIMENTAL
Intervention: Therapists' adherence ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervisors' adherence ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TSF expert raters' adherence ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External raters' adherence ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall adherence ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapists' reliability ratings
Number of subjects: 0
Study: 22854545

Group type: EXPERIMENTAL
Intervention: Pre-operative visual information and parental presence
Number of subjects: 76
Study: 19464208

Group type: EXPERIMENTAL
Intervention: Root ZX II meter reading set at '0.5'
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Root ZX II meter reading set at '1'
Number of subjects: 70
Study: 19808266

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg/d
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 16178946

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12174922

Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate 11.25 mg subcutaneous injection every three months for 2 years
Number of subjects: 589

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 500 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2, days 1 and 8, q 4 weeks)
Number of subjects: 589
Study: 10441862

Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kg per day, adjusted to 0.25 mg/kg per day on alternate days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8882570

Group type: EXPERIMENTAL
Intervention: Deflazacort (DFC) 0.9 mg/kg/day
Number of subjects: 67

Group type: COMPARATOR
Intervention: Prednisone (PRED) 0.75 mg/kg/day
Number of subjects: 67
Study: 2193556

Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA) with oxybuprocain‐hydrochloride 1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: General Anaesthesia (GA) with midazolam, piritramide and vecuronium bromide
Number of subjects: 30
Study: 387494

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study: 31867778

Group type: EXPERIMENTAL
Intervention: Video plus routine care
Number of subjects: 332

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Video plus routine care (intervention group)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Subset of patients who had previously undergone a similar procedure
Number of subjects: 332
Study: 30657179

Group type: EXPERIMENTAL
Intervention: Yoga program, twice a week for 6 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 128
Study: 27984472

Group type: EXPERIMENTAL
Intervention: Weekly spinal stabilization exercises
Number of subjects: 32

Group type: COMPARATOR
Intervention: 1-time treatment and home exercise program
Number of subjects: 32
Study: 25887430

Group type: EXPERIMENTAL
Intervention: MediMind
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Autogenic Training
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study: 23998244

Group type: EXPERIMENTAL
Intervention: Atopic dermatitis and/or allergic rhinitis
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 2008-2009 seasonal influenza vaccine
Number of subjects: 168
Study: 21869628

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 24
Study: 19675485

Group type: EXPERIMENTAL
Intervention: Independent Cranks (IC) training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Independent Cranks (IC) training followed by Normal Cranks (NC) retention test
Number of subjects: 18
Study: 18065067

Group type: EXPERIMENTAL
Intervention: Imagery intervention combined with technical practice
Number of subjects: 48

Group type: COMPARATOR
Intervention: Technical practice only
Number of subjects: 48
Study: 15153593

Group type: EXPERIMENTAL
Intervention: 20 mg parecoxib sodium
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib sodium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 12069102

Group type: EXPERIMENTAL
Intervention: 30 mg of Q10 (maximum daily dose recommended)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg of Q10 (dose-dependent increase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Q10 supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Q10 with minor vitamin E dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose vitamin E supplementation
Number of subjects: 0
Study: 9665594

Group type: EXPERIMENTAL
Intervention: Real magnetic stimulation (40 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham magnetic stimulation (40 min)
Number of subjects: 30
Study: 7481863

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin plus cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (175 mg/m2 in a 3-hour infusion)
Number of subjects: 0
Study: 2651015

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg) twice daily for 4 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (identical looking tablet) twice daily for 4 weeks
Number of subjects: 56
Study: 368744

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 14

Group type: COMPARATOR
Intervention: Oxprenolol
Number of subjects: 14
Study: 31455482

Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small Group Discussion (SGD)
Number of subjects: 0
Study: 28757482

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hsTnI)
Number of subjects: 1081
Study: 26964166

Group type: EXPERIMENTAL
Intervention: Acupoint injection of shuang huanglian injection (1 mL at each point, three times a week for 2 weeks) and fire needling (once a day for 3 times)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Oral administration of vitamin C (100 mg, three times a day) and vitamin B2 (20 mg, three times a day) and subcutaneous injection of transfer factor (2 mL, twice a week for 2 weeks)
Number of subjects: 158
Study: 22899659

Group type: EXPERIMENTAL
Intervention: Perceived Deficits Questionnaire (PDQ; range 0‐20)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Total cognitive function score (range 0‐16)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis controlling for various factors
Number of subjects: 120
Study: 21762358

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg
Number of subjects: 984

Group type: COMPARATOR
Intervention: Valsartan 320 mg
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg and 80 mg
Number of subjects: 984
Study: 19347979

Group type: EXPERIMENTAL
Intervention: Daily oral carboxyaminoimidazole
Number of subjects: 186
Study: 16461612

Group type: EXPERIMENTAL
Intervention: High perceived seriousness of acquiring a sexually transmitted infection
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Having 'other' (not steady) partners in the last 6 months
Number of subjects: 376
Study: 15304143

Group type: EXPERIMENTAL
Intervention: Training in shared decision making (SDM) skills and risk communication materials
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Risk communication intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SDM intervention
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Female doctors
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Time constraints
Number of subjects: 20
Study: 10816230

Group type: EXPERIMENTAL
Intervention: External ultrasound (EUS) therapy applied at therapeutic energies
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo settings
Number of subjects: 25
Study: 8968180

Group type: EXPERIMENTAL
Intervention: Controlled hypotension using sodium nitroprusside
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no hypotension)
Number of subjects: 40
Study: 1758394

Group type: EXPERIMENTAL
Intervention: Intravenous Cyclophosphamide
Number of subjects: 1

Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 1
Study: 6122770

Group type: EXPERIMENTAL
Intervention: Danazol 200 mg/day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Danazol 400 mg/day
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31126542

Group type: EXPERIMENTAL
Intervention: Cheongsangbangpoong-tang (CBT) 5g extract, three times a day for 8 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo 5g extract, three times a day for 8 weeks
Number of subjects: 56
Study: 30169215

Group type: EXPERIMENTAL
Intervention: PPOIT (Probiotic and Peanut Oral Immunotherapy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PPOIT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25811286

Group type: EXPERIMENTAL
Intervention: Sujon New Zealand blackcurrant powder (6g/day)
Number of subjects: 13
Study: 24662446

Group type: EXPERIMENTAL
Intervention: Standardised self‐completed study measurement instruments
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Strategies used by interviewees (adding notes, adding response categories, skipping an item)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Educational materials addressing differential logics
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pilot testing validated instruments using cognitive interviews
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Method for participants to convey personal experiences
Number of subjects: 20
Study: 22970658

Group type: EXPERIMENTAL
Intervention: Flupirtine MR 400 mg OD
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Tramadol ER 200 mg OD
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 19895369

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition without intervention
Number of subjects: 14
Study: 18070259

Group type: EXPERIMENTAL
Intervention: Exploratory Factor Analysis (EFA) on sample of 9,856 participants
Number of subjects: 19777

Group type: EXPERIMENTAL
Intervention: Confirmatory Factor Analysis (CFA) on sample of 9,921 participants
Number of subjects: 19777
Study: 16214026

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6) levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin-1 receptor antagonist (IL-1ra) levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 0
Study: 11828898

Group type: EXPERIMENTAL
Intervention: Single-vision lenses
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bifocal glasses
Number of subjects: 71
Study: 9873237

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for infertile couples
Number of subjects: 17
Study: 7669460

Group type: EXPERIMENTAL
Intervention: Ketorolac before operation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no ketorolac)
Number of subjects: 90
Study: 2572609

Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 23

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 23
Study: 1207761

Group type: EXPERIMENTAL
Intervention: Tyramine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31593215

Group type: EXPERIMENTAL
Intervention: Bayesian weighted Mendelian randomization (BWMR)
Number of subjects: 0
Study: 31173150

Group type: EXPERIMENTAL
Intervention: 5-fraction hypofractionated stereotactic radiotherapy (HSRT) with a median total dose of 30 Gy (range, 25-35 Gy)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5-fraction hypofractionated stereotactic radiotherapy (HSRT)
Number of subjects: 122
Study: 28339554

Group type: EXPERIMENTAL
Intervention: Antazoline (up to 250 mg intravenously)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Antazoline
Number of subjects: 74
Study: 25940675

Group type: EXPERIMENTAL
Intervention: PF‐05231023 (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF‐05231023 (high-dose groups)
Number of subjects: 0
Study: 23836190

Group type: COMPARATOR
Intervention: Lapatinib 900 mg/m² dose bid for 7-14 days (pre-resection treatment)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lapatinib continuously at 900 mg/m² dose bid in phase II study
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 42
Study: 22100793

Group type: EXPERIMENTAL
Intervention: Less relevant questionnaire (10 items)
Number of subjects: 6447

Group type: COMPARATOR
Intervention: Additional questionnaire length (23 or 34 items)
Number of subjects: 6447

Group type: EXPERIMENTAL
Intervention: Pooled analysis across all four follow-up intervals
Number of subjects: 6447
Study: 19692495

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 microg Se/d as l-selenomethionine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iodine supplementation (80 microg I)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Selenium + Iodine supplementation (100 microg Se + 80 microg I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21233084

Group type: EXPERIMENTAL
Intervention: 2-hour e-learning programme focused on the recognition of child abuse
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no e-learning programme)
Number of subjects: 38
Study: 15825778

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 55
Study: 12066721

Group type: EXPERIMENTAL
Intervention: Group H (30% blood volume withdrawn and replaced with saline)
Number of subjects: 20
Study: 11477907

Group type: EXPERIMENTAL
Intervention: Ligustrazine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Common treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 7867683

Group type: COMPARATOR
Intervention: benazepril (10 mg) + amlodipine (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: benazepril (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: benazeprilat (after benazepril + amlodipine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: benazeprilat (after benazepril)
Number of subjects: 12

Group type: COMPARATOR
Intervention: amlodipine (5 mg) + benazepril (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: amlodipine (5 mg)
Number of subjects: 12
Study: 2464919

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (encainide, flecainide, moricizine, imipramine)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 502
Study: 2092

Group type: EXPERIMENTAL
Intervention: Metoprolol 20 mg t.i.d.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11598040

Group type: EXPERIMENTAL
Intervention: GBS type III CPS‐tetanus toxoid (III‐TT) conjugate vaccine with alum (12.5 microg dose)
Number of subjects: 51

Group type: COMPARATOR
Intervention: GBS type III CPS‐tetanus toxoid (III‐TT) conjugate vaccine without alum (12.5 microg dose)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Second dose of GBS III‐TT conjugate vaccine (12.5 microg dose) administered 21 months after the first dose
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Second dose of GBS III‐TT conjugate vaccine (12.5 microg dose) for participants with undetectable III CPS‐specific IgG before the first dose
Number of subjects: 51
Study: 31793602

Group type: EXPERIMENTAL
Intervention: Drink containing 14 wt% digestible CHO, 0.2 wt% HM-pectin/alginate, 0.06 wt% sodium chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29549516

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 27036920

Group type: EXPERIMENTAL
Intervention: Closed-suction drain
Number of subjects: 83

Group type: COMPARATOR
Intervention: No closed-suction drain
Number of subjects: 83
Study: 24552609

Group type: EXPERIMENTAL
Intervention: Touch-screen mode of administration
Number of subjects: 99

Group type: COMPARATOR
Intervention: Paper-and-pencil mode of administration
Number of subjects: 99
Study: 22143612

Group type: EXPERIMENTAL
Intervention: DTR-preserved patients
Number of subjects: 213
Study: 20210911

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both MBCT and CBT
Number of subjects: 26
Study: 17562672

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20479

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 20479
Study: 16330736

Group type: EXPERIMENTAL
Intervention: Bed-wetting
Number of subjects: 1666
Study: 12497978

Group type: EXPERIMENTAL
Intervention: Quinine (Group 1a)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Artesunate (Group 1b)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Artesunate (Group 2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Severe cases (Groups 1a and 1b)
Number of subjects: 14
Study: 9866361

Group type: EXPERIMENTAL
Intervention: Portable capillary whole blood coagulation monitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Venipuncture/laboratory method
Number of subjects: 0
Study: 7649579

Group type: EXPERIMENTAL
Intervention: Perindopril (2 or 4 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/d)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Perindopril and Amlodipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: All treatments together
Number of subjects: 10
Study: 2764234

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 40
Study: 180619

Group type: EXPERIMENTAL
Intervention: Hepatic dearterialization
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion of 5-fluorouracil
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Hepatic arterial ligation and portal venous infusion of 5-fluorouracil
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 406

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 406
Study: 30701387

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 29189032

Group type: EXPERIMENTAL
Intervention: Network analysis of depression and PTSD symptoms
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Network comparisons across risk groups
Number of subjects: 296
Study: 25368978

Group type: EXPERIMENTAL
Intervention: Higher protein (HP) infant formula (2.05 g per 100 mL)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Lower protein (LP) infant formula (1.25 g per 100 mL)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Breast-fed
Number of subjects: 691
Study: 23696612

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505

Group type: COMPARATOR
Intervention: LBBB
Number of subjects: 6505
Study: 21425620

Group type: EXPERIMENTAL
Intervention: Low power laser (LPL) treatment, frequency of 73 Hz, 10 minutes per treatment, total dose 15 J.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low power laser (LPL) treatment.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conservative methods of physical medicine (electrotherapy: diadynamic currents, interferent currents, electrophoresis with novocaine).
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conservative methods of physical medicine.
Number of subjects: 70
Study: 19485585

Group type: EXPERIMENTAL
Intervention: Parent management training
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Attendance in parent management training
Number of subjects: 445
Study: 16928838

Group type: EXPERIMENTAL
Intervention: Tdap vaccine (Sanofi Pasteur - Adacel and GlaxoSmithKline - Boostrix)
Number of subjects: 229
Study: 12605039

Group type: EXPERIMENTAL
Intervention: Systemic linoleic acid (LA) 28.5 mg and gamma-linolenic acid (GLA) 15 mg twice daily for 45 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group received a tear substitute and a placebo tablet for 45 days
Number of subjects: 26
Study: 11185632

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g + telmisartan 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg three times daily + telmisartan 120 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetaminophen 1 g
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg three times daily
Number of subjects: 12
Study: 8570137

Group type: EXPERIMENTAL
Intervention: Chemotherapy (Ctx) and/or radiotherapy (Rtx)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 81
Study: 1322385

Group type: EXPERIMENTAL
Intervention: Benign breast disease (aggregate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proliferative benign breast disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-proliferative benign breast disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lobular carcinoma in situ and ductal carcinoma in situ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mathematical models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast cancer prevention trials
Number of subjects: 0
Study: 6496180

Group type: EXPERIMENTAL
Intervention: Nicholson score for prescribing digoxin
Number of subjects: 84